Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus

 Novartis Reports Results of Galvus (vildagliptin) Combination Therapy in P-IV VERIFY Study for Type 2 Diabetes Mellitus

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Shots:

  • The P-IV VERIFY study involves assessing of Galvus (50mg, bid) + Metformin (1000–2000 mg, qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a ratio (1:1), recently diagnosed with T2DM across 34 countries for 5yrs.
  • The P-IV VERIFY study resulted in meeting its 1EPs i.e, 49% reduction in the risk for time to initial treatment failure as defined as HbA1c >=7%, showed a lower frequency of secondary failure with consistent safety & tolerability profile
  • Vildagliptin/Metformin dual regimen is the combination of two anti-diabetic agents with complementary mechanism and is the single pill dual therapy of DPP-4 inhibitor with metformin to be approved in Japan & Europe

Click here to­ read full press release/ article | Ref: Novartis | Image: Pharma News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post